Detalhe da pesquisa
1.
RGC-32 mediates proinflammatory and profibrotic pathways in immune-mediated kidney disease.
Clin Immunol
; 265: 110279, 2024 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38878807
2.
Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects against Pulmonary Fibrosis.
Am J Respir Cell Mol Biol
; 66(2): 146-157, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34668840
3.
RGC-32' dual role in smooth muscle cells and atherogenesis.
Clin Immunol
; 238: 109020, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35462050
4.
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.
Mult Scler
; 28(11): 1729-1743, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768939
5.
JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.
Clin Immunol
; 210: 108297, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31698073
6.
Intracerebral matrix metalloproteinase 9 in fatal diabetic ketoacidosis.
Exp Mol Pathol
; 108: 97-104, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30986397
7.
RGC-32 Promotes Th17 Cell Differentiation and Enhances Experimental Autoimmune Encephalomyelitis.
J Immunol
; 198(10): 3869-3877, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28356385
8.
Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Exp Mol Pathol
; 105(2): 175-180, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30028960
9.
CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the ParentâF1 Graft-versus-Host Disease Model.
J Immunol
; 196(4): 1529-40, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26792801
10.
Markers of immune-mediated inflammation in the brains of young adults and adolescents with type 1 diabetes and fatal diabetic ketoacidosis. Is there a difference?
Exp Mol Pathol
; 102(3): 505-514, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28533125
11.
SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
Exp Mol Pathol
; 102(2): 191-197, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28109694
12.
RGC-32 is expressed in the human atherosclerotic arterial wall: Role in C5b-9-induced cell proliferation and migration.
Exp Mol Pathol
; 101(2): 221-230, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27619159
13.
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Exp Mol Pathol
; 99(3): 498-505, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26407760
14.
RGC-32 is a novel regulator of the T-lymphocyte cell cycle.
Exp Mol Pathol
; 98(3): 328-37, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25770350
15.
Letter by Rus et al Regarding Article, "RGC-32 (Response Gene to Complement 32) Deficiency Protects Endothelial Cells From Inflammation and Attenuates Atherosclerosis".
Arterioscler Thromb Vasc Biol
; 38(6): e96, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793993
16.
SIRT1 is decreased during relapses in patients with multiple sclerosis.
Exp Mol Pathol
; 96(2): 139-48, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24397908
17.
IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms.
J Immunol
; 189(2): 1081-93, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22723520
18.
The liver and muscle secreted HFE2-protein maintains central nervous system blood vessel integrity.
Nat Commun
; 15(1): 1037, 2024 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310100
19.
Dual role of Response gene to complement-32 in multiple sclerosis.
Exp Mol Pathol
; 94(1): 17-28, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23000427
20.
COVID, complement, and the brain.
Front Immunol
; 14: 1216457, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533859